Last reviewed · How we verify
over dose
Naloxone works by binding to opioid receptors in the brain, reversing the effects of opioid overdose.
Naloxone works by binding to opioid receptors in the brain, reversing the effects of opioid overdose. Used for Reversal of opioid overdose.
At a glance
| Generic name | over dose |
|---|---|
| Also known as | Domperidone Suspension(Motilium), B12200018238 |
| Sponsor | Nanfang Hospital, Southern Medical University |
| Drug class | opioid antagonist |
| Target | opioid receptor |
| Modality | Small molecule |
| Therapeutic area | Emergency Medicine |
| Phase | FDA-approved |
Mechanism of action
Naloxone is a competitive antagonist of the opioid receptor, which means it binds to the same receptors as opioids but does not activate them. This binding action reverses the effects of opioids, including respiratory depression, sedation, and euphoria.
Approved indications
- Reversal of opioid overdose
Common side effects
- Nausea
- Vomiting
- Headache
- Hypotension
- Tachycardia
Key clinical trials
- Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial (PHASE1)
- Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer (PHASE3)
- Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors (PHASE1)
- Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma (PHASE1, PHASE2)
- Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN (PHASE1, PHASE2)
- Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL (PHASE1, PHASE2)
- Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients (PHASE2)
- Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- over dose CI brief — competitive landscape report
- over dose updates RSS · CI watch RSS
- Nanfang Hospital, Southern Medical University portfolio CI